Venetoclax: A new wave in hematooncology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YXL" target="_blank" >RIV/61988987:17110/18:A1901YXL - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/18:E0107015

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.exphem.2018.02.002" target="_blank" >http://dx.doi.org/10.1016/j.exphem.2018.02.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.exphem.2018.02.002" target="_blank" >10.1016/j.exphem.2018.02.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Venetoclax: A new wave in hematooncology

Popis výsledku v původním jazyce

nhibitors of antiapoptotic proteins of the BCL2 family can successfully restart the deregulated process of apoptosis in malignant cells. Whereas nonselective agents have been limited by their affinity to different BCL2 members, thus inducing excessive toxicity, the highly selective BCL2 inhibitor venetoclax (ABT-199, Venclexta (TM)) has an acceptable safety profile. To date, it has been approved in monotherapy for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) with 17p deletion. Extension of indications can be expected in monotherapy and in combination regimens. Sensitivity to venetoclax is not common in lymphomas, but promising outcomes have been achieved in the mantle cell lymphoma group. Venetoclax is also active in multiple myeloma patients, especially in those with translocation t(11;14), even if high-risk features such as dell7p are also present. Surprisingly, positive results are being obtained in elderly acute myeloid leukemia patients, in whom inhibition of BCL2 is able to substantially increase the efficacy of low-dose cytarabine or hypomethylating agents. Here, we provide a summary of available results from clinical trials and describe a specific mechanism of action that stands behind the efficacy of venetoclax in hematological malignancies. (C) 2018 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Název v anglickém jazyce

Venetoclax: A new wave in hematooncology

Popis výsledku anglicky

nhibitors of antiapoptotic proteins of the BCL2 family can successfully restart the deregulated process of apoptosis in malignant cells. Whereas nonselective agents have been limited by their affinity to different BCL2 members, thus inducing excessive toxicity, the highly selective BCL2 inhibitor venetoclax (ABT-199, Venclexta (TM)) has an acceptable safety profile. To date, it has been approved in monotherapy for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) with 17p deletion. Extension of indications can be expected in monotherapy and in combination regimens. Sensitivity to venetoclax is not common in lymphomas, but promising outcomes have been achieved in the mantle cell lymphoma group. Venetoclax is also active in multiple myeloma patients, especially in those with translocation t(11;14), even if high-risk features such as dell7p are also present. Surprisingly, positive results are being obtained in elderly acute myeloid leukemia patients, in whom inhibition of BCL2 is able to substantially increase the efficacy of low-dose cytarabine or hypomethylating agents. Here, we provide a summary of available results from clinical trials and describe a specific mechanism of action that stands behind the efficacy of venetoclax in hematological malignancies. (C) 2018 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

O - Projekt operacniho programu

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EXPERIMENTAL HEMATOLOGY

ISSN

0301-472X

e-ISSN

1873-2399

Svazek periodika

—

Číslo periodika v rámci svazku

61

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

16

Strana od-do

10-25

Kód UT WoS článku

000430637200002

EID výsledku v databázi Scopus

2-s2.0-85044294896